Candel Therapeutics reports phase 3 prostate cancer biomarker data
The company said the data from its completed aglatimagene besadenovec trial showed sustained immune remodeling more than two years after treatment versus radiotherapy alone.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.
News Feed
2 results loaded, newest first. End of these results. The latest changes are still being indexed. Try again shortly for updated results.
Candel Therapeutics, Inc. (CADL) Reports Sustained Immune Remodeling in Phase 3 Prostate Study
Candel Therapeutics reported AI-enabled digital pathology from its completed Phase 3 aglatimagene study showing significantly increased intratumoral lymphocyte infiltration vs placebo more than two years post-EBRT, supporting prior disease-free survival and pathologic outcome findings.Material Deta…